
Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap. Get the full industry report at lnkd.in/eeSbk4ba #AI

Talking biopharmaceuticals, biotechnology, bioprocessing and related pharma manufacturing.

Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap. Get the full industry report at lnkd.in/eeSbk4ba #AI

A C1q-binding assay you can’t trust puts your antibody’s CDC story in question. On Nov. 18, Han Yang of sponsor WuXi Biologics shows how they qualified a label-free BLI method. Design & qualification results, free: hubs.li/Q04Fd_Qr0

CAR-T changed blood cancer care. Solid and brain tumors are a different challenge: cells must reach, penetrate, and survive inside a physical tumor mass. 🔗 See the 3 barriers in the way, free with sign-in: hubs.li/Q04DzTNs0 #BioPharm #CARTCells #Oncology

One company’s reason to walk away is another’s opportunity. When Big Pharma drops a drug candidate, smaller developers are often the ones who pick it up, but a second chance isn’t a guarantee. Get the free FAQ here➡️ hubs.li/Q04CLMrW0 #BioPharm #DrugDevelopment

Dr Karu Sukuru of @Catalent_ explains why patient-centric formulation design is advancing oral peptide drug development, a theme from his #PharmSci360 talk. @AAPSComms 🎥 Watch now: hubs.li/Q04CFmRc0 #PeptideDrugDelivery #FormulationDevelopment #AAPS2026

Drug developers are increasingly treating their suppliers as strategic partners. Meeta Gulyani of @Ecolab on why that’s changing & where biomanufacturing is headed next. 📽️ Hear the trends shaping bioprocessing hubs.li/Q04B6QlR0 #BioProcessing

Can AI predict which drug molecules fit platform formulations? AI-guided formulation development depends on high-quality data and stability outcomes, says @pfizer's Dr Johnson at #PharmSci360. 🎥 Learn more: hubs.li/Q04CvclP0 #AIinDrugDevelopment #FormulationScience

In today's The BioPharm Brief: New clinical data highlight ADCs in cancer and CAR T-cell therapy for multiple sclerosis, including survival gains, modest benefit, and safety risks. 🎧 Listen: hubs.li/Q04CnS4M0 #DrugDevelopment #CARTCellTherapy

How can pharma entrepreneurship reshape drug development economics? At #AAPS2026 #PharmSci360, @averincapital's @DavidBerry26 will explore innovation and investment in life sciences at the closing plenary. Read more: hubs.li/Q04Cm-qy0 #DrugDevelopment #PharmaInnovation

Would your bispecific program hold up in a tech transfer tomorrow? Mispaired species and aggregation cut yield and investor confidence. How to catch them early, with FUJIFILM Biotechnologies: hubs.li/Q04ytbKC0

Cell therapy developers are pivoting from ex vivo to in vivo CAR-T. A 2026 review projects in vivo could cut treatment-course costs by 50% or more. Still a projection. 🔗 What in vivo still has to prove (free sign-in): hubs.li/Q04BTkQR0 #BioPharm #CellTherapy

Can we trust agentic AI for risk assessment? Traceable evidence, transparent decisions, and verifiable outcomes are essential. 🎥 Learn more from Insilica CEO Thomas Luechtefeld ahead of @AAPSComms #PharmSci360: hubs.li/Q04BYS3j0 #AgenticAI #DrugDevelopment

How can biomarker testing improve access to targeted cancer therapies? @bmsnews’s Dr @n8pennell explains key barriers in precision oncology, from tissue collection to patient education. 🎥 Learn more: hubs.li/Q04BBHR40 #PrecisionOncology #BiomarkerTesting #CancerResearch

At #ACG2026, @Odyssey_Tx is presenting a phase 2a trial design evaluating oral RIPK2 inhibitor OD-001 plus vedolizumab in moderate-to-severe UC. Topline induction results are expected in H2 2027. 👉 Read now: hubs.li/Q04zWMK10 #UlcerativeColitis #DrugDevelopment

Today's BioPharm Brief covers FDA-approved atezolizumab for stage 3 dMMR colon cancer, positive phase 3 data for thyroid eye disease, and petrelintide’s weight-loss results in phase 2b testing. 🎧 Listen now: hubs.li/Q04zQpcv0 #DrugDevelopment #ClinicalTrials #Biopharma

Dr. Nathan Pennell of Bristol Myers Squibb explains why MRD-negative complete response matters as longer patient survival delays traditional clinical trial endpoints. 🎥 Watch his interview now: hubs.ly/Q04zN7hy0 #MultipleMyeloma #ClinicalTrials